Navigation Links
Phase 2 Clinical Results of Ganite Plus Standard Therapy in,Patients with Relapsed/Refractory Lymphoma Presented at ASCO

DA”) or European Medicines Agency
(“EMEA”);
• the safety and efficacy of the Company’s products or product candidates;
• the Company’s assessment of its clinical trials;
• the commencement and completion of clinical trials;
• the Company’s ability to develop, manufacture, license and sell its products or product
candidates;
• the Company’s ability to enter into and successfully execute license and collaborative
agreements, if any;
• the adequacy of the Company’s capital resources and cash flow projections, and the
Company’s ability to obtain sufficient financing to maintain the Company’s planned
operations;
• the adequacy of the Company’s patents and proprietary rights;
• the impact of litigation that has been brought against the Company and its officers and
directors and any proposed settlement of such litigation;
• the Company’s ability to regain compliance with the NASDAQ’s listing qualifications, or
its ability to successfully appeal the NASDAQ delisting; and
• the other risks described under Certain Risks and Uncertainties Related to the
Company’s Business, as contained in the Company’s Annual Report on Form 10-K and
Quarterly Report on Form 10-Q.

The Company does not undertake to update any forward-looking statements. There are a
number of factors that could cause actual results and developments to differ materially. For a
discussion of those risks and uncertainties, please see the Company's Annual Report on Form
10-K for 2006 and its most recent quarterly report on Form 10-Q.

CONTACT:
For Genta Incorporated
Tara Spiess/Andrea Romstad
TS Communications Group, LLC
(908) 286-3980
info@genta.c
'"/>





Page: 1 2 3 4 5

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
3. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
7. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
8. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
9. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
10. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
11. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
Post Your Comments:
(Date:9/2/2015)... -- Research and Markets ( http://www.researchandmarkets.com/research/hcb7bz/pharmaceutical ) has announced ... UK - November 16-18, 2015)" conference to their offering. ... including Columbia, Peru , Brazil ... Uruguay , Paraguay , Venezuela ... , Chile This seminar can be ...
(Date:9/2/2015)... -- Research and Markets ( http://www.researchandmarkets.com/research/cnq7tc/medical_device ) has ... Studies: Clinical Evidence (London, UK - November 10-11, ... This course has been designed specifically for ... required for medical devices and in-vitro diagnostic products. ... and the emphasis on high quality, appropriate clinical ...
(Date:9/2/2015)... Research and Markets ( http://www.researchandmarkets.com/research/r6wspz/drug_delivery_in ) ... report "Drug Delivery in Central Nervous System ... their offering. Advances in understanding ... opened new avenues and possibilities for improved drug ... systems, enzymes, and receptors that control the penetration ...
Breaking Medicine Technology:Pharmaceutical Regulatory Affairs in Latin America Seminar - London, UK - November 16-18, 2015 2Medical Device Studies: Clinical Evidence Course - London, UK - November 10-11, 2015 2Drug Delivery in Central Nervous System Diseases - Technologies, Markets and Companies Report 2015-2024 2Drug Delivery in Central Nervous System Diseases - Technologies, Markets and Companies Report 2015-2024 3
... Broadspire, a Crawford Company (NYSE: CRDA ; CRDB) ... provider, is proud to announce that Gary Anderberg, Ph.D., practice ... of Risk & Insurance magazine,s 2010 Risk Innovator ... a leader with Broadspire,s e-Triage system, which helps analyze claims ...
... Pa., Sept. 15 The GBS /CIDP ... symposium on Guillain-Barre Syndrome (GBS) and Chronic Inflammatory ... 5-7, 2010.  Over 400 medical professionals, current and former ... expected to attend the three-day event at the Dolce ...
Cached Medicine Technology:Broadspire’s Gary Anderberg Named a 2010 Risk Innovator 2Broadspire’s Gary Anderberg Named a 2010 Risk Innovator 3GBS/CIDP Foundation to Hold 11th International Symposium 2
(Date:9/3/2015)... ... September 03, 2015 , ... ... triggering cost increases for fully insured employer-sponsored health insurance plans, more employers are ... employees), according to data released from the 2014 United Benefit Advisors (UBA) Health ...
(Date:9/3/2015)... ... September 03, 2015 , ... ... endpoint data collection, cloud analytics and workflow solutions today announced the complete ... Portugal, September 22-24, 2015. The esteemed faculty of worldwide pharmaceutical and industry ...
(Date:9/3/2015)... ... , ... AvePoint, the established leader in enabling enterprise collaboration across ... – AvePoint’s solution for facilitating two-way collaboration and external sharing without ever having to ... is the fifth consecutive year an AvePoint product has made the list. , The ...
(Date:9/3/2015)... ... September 03, 2015 , ... The new In-Office ... of Provo, Utah. The Clinicians Report is a leading information source to the ... throughout the U.S. Whiter Image's In-Office whitening kits were favorably validated for use ...
(Date:9/3/2015)... (PRWEB) , ... September 03, 2015 , ... Local filmmakers ... April Hannah & Michael Habernig from Path 11 Productions have had great success in ... age podcast has featured Hay House authors, Teal Swan who is the well known ...
Breaking Medicine News(10 mins):Health News:Self-Funded Pharmacy Plans Becoming More Popular Among Large Employers 2Health News:Self-Funded Pharmacy Plans Becoming More Popular Among Large Employers 3Health News:Self-Funded Pharmacy Plans Becoming More Popular Among Large Employers 4Health News:ERT Announces Final Agenda, Faculty for European PRO / eCOA Congress 2Health News:ERT Announces Final Agenda, Faculty for European PRO / eCOA Congress 3Health News:AvePoint Perimeter Named a “KMWorld 2015 Trend-Setting Product” 2Health News:AvePoint Perimeter Named a “KMWorld 2015 Trend-Setting Product” 3Health News:AvePoint Perimeter Named a “KMWorld 2015 Trend-Setting Product” 4Health News:Whiter Image Products Get Positive Rating From The Clinicians Report 2Health News:Path 11 Podcast Now Features over 20 Metaphysical Discussions on iTunes and Growing 2Health News:Path 11 Podcast Now Features over 20 Metaphysical Discussions on iTunes and Growing 3
... may be able to help people// suffering from fibromyalgia. ... of Florida the cough medicine seemed to bring relief ... from fibromyalgia. ,Fibromyalgia syndrome occurs with extensive musculo-skeletal ... this diseases. More women than men report to be ...
... that asthmatic women have tendency of// irregular menstruation. ... severe stress, serious disease, anorexia nervosa, and drug addiction. ... women for 8 years to understand the possible link ... the research said that younger women with asthma and ...
... Scientists said that the problem of inability to read ... in visual processes as was thought in recent years. ... of perception than anything else. ,Dyslexia is one ... children, who have difficulty in verbal skills, abstract reasoning, ...
... researchers have established the association between adult urinary incontinence ... than 1000 Turkish women, the research says that the ... same for exhibiting lack of control in controlling urine ... may suffer from some faulty neural pathway that connects ...
... apnea syndrome affects a lot of people who are ... of having a difficult night, these people may have ... ,Obstructive sleep apnea syndrome (OSAS), also known as the ... problems, stroke, obesity, breathing problems, sexual dysfunction and clinical ...
... Women who had been diagnosed with breast cancer need to ... with lowering of levels of ovarian hormones and this could ... cancer patients who regularly exercised for about an hour daily. ... Health Study who were diagnosed with breast cancer of stages ...
Cached Medicine News:
... The Eppendorf Mastercycler Family offers fast temperature ... for optimal flexibility. Personal cards enable safe ... reliable transfer of individual protocols between different ... for PCR and come with a two-year ...
96 well thermocycler with unique High Temperature Range (HTR) Peltier technology for fastest available heating and cooling rates up to 4C/sec with High Pressure Lid for automated sealing of PCR plate...
... 40 or 96 temperature cyclers, the gradient block ... range of up to 14 or 22 across ... temperature difference of up to 2C between adjacent ... test up to 12 different annealing temperatures in ...
... performance, high sample throughput instrument at a highly ... Flexible block format, a newly designed flexible heated ... Includes a four year or 80,000 Cycle Warranty! ... connected and run through a PC using Gensoft, ...
Medicine Products: